• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed

    12/28/20 6:08:24 PM ET
    $PTI
    Major Pharmaceuticals
    Health Care
    Get the next $PTI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Robertson Brigitte

    (Last) (First) (Middle)
    C/O YUMANITY THERAPEUTICS, INC
    40 GUEST STREET, SUITE 4410

    (Street)
    BOSTON MA 02135

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/22/2020
    3. Issuer Name and Ticker or Trading Symbol
    YUMANITY THERAPEUTICS, INC. [ YMTX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned. Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Brigitte Robertson 12/28/2020
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

    Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka

    4/24/24 3:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio

    BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at 9:00 a.m. Eastern Time on December 22, 2020 (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated August 22, 2020, as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned s

    12/22/20 10:47:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    Yumanity Therapeutics to Raise $33.6 Million PIPE Contingent on Completion of Reverse Merger with Proteostasis

    Leading institutional investors commit $33.6 million through a common stock private investment in public equity (“PIPE”) led by Fidelity Management & Research Company, LLC and Invus Proteostasis plans to adjourn its special meeting of stockholders to December 22, 2020 BOSTON, Mass., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, and Proteostasis Therapeutics, Inc. (Nasdaq: PTI) today announced that Proteostasis has entered into a definitive agreement for the sale of its Common Stock in a private placement led by Fidelity

    12/15/20 7:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    $PTI
    SEC Filings

    View All

    SEC Form SC 13G filed

    SC 13G - YUMANITY THERAPEUTICS, INC. (0001445283) (Subject)

    1/11/21 10:51:55 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    SEC Form 8-K filed

    8-K - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

    1/11/21 6:30:35 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    SEC Form D filed

    D - YUMANITY THERAPEUTICS, INC. (0001445283) (Filer)

    1/6/21 5:28:17 PM ET
    $PTI
    Major Pharmaceuticals
    Health Care

    $PTI
    Leadership Updates

    Live Leadership Updates

    View All

    Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

    Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop next generation therapeutics for neurodegenerative diseases, today announced the appointment of Ms. Meenu Chhabra Karson as Chair of its Board of Directors. An experienced biopharma executive, Ms. Chhabra Karson will lend her business, scientific and operational expertise towards helping Harness achieve its next phase of growth as it advances its oligonucleotide-based platform for controlled upregulation of CNS targets and its lead programme in Huntington's disease. Ms. Chhabra Ka

    4/24/24 3:00:00 AM ET
    $PTI
    Major Pharmaceuticals
    Health Care